

Brigette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9480289/publications.pdf>

Version: 2024-02-01

225
papers

15,034
citations

30047

54
h-index

19726

117
g-index

228
all docs

228
docs citations

228
times ranked

16271
citing authors

#	ARTICLE	IF	CITATIONS
1	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
2	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. <i>Journal of Clinical Oncology</i> , 2015, 33, 3356-3364.	0.8	579
3	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 619-629.	5.1	574
4	A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α -2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1532-1538.	3.0	567
5	Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 513-522.	13.9	531
6	Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 242-249.	0.8	487
7	Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2005, 97, 536-539.	3.0	449
8	Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1614-1619.	3.0	384
9	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18761-18768.	3.3	363
10	Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5414-5418.	0.8	346
11	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). <i>Journal of Clinical Oncology</i> , 2018, 36, 1412-1418.	0.8	324
12	Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3568-3576.	0.8	277
13	New Utility of an Old Marker: Serial α -Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 446-452.	0.8	241
14	Exome and genome sequencing of nasopharynx cancer identifies NF- κ B pathway activating mutations. <i>Nature Communications</i> , 2017, 8, 14121.	5.8	227
15	Nasopharyngeal carcinoma: an evolving paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 679-695.	12.5	207
16	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 840-859.	0.8	178
17	Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2014, 25, 1204-1208.	0.6	175
18	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3361-3367.	0.8	167

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma? a prospective study. <i>Head and Neck</i> , 2003, 25, 864-872.	0.9	165
20	Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. <i>Cancer Research</i> , 2013, 73, 1676-1688.	0.4	159
21	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , 2019, 29, 418-427.	2.4	159
22	Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. <i>Cancer</i> , 2003, 98, 288-291.	2.0	154
23	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Annals of Oncology</i> , 2004, 15, 1661-1666.	0.6	153
24	The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 650-658.	1.2	149
25	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3091-3100.	0.8	147
26	A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. <i>Investigational New Drugs</i> , 2008, 26, 169-173.	1.2	142
27	Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents. <i>Journal of Clinical Oncology</i> , 2003, 21, 2760-2776.	0.8	131
28	Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. <i>Clinical Cancer Research</i> , 2018, 24, 1824-1833.	3.2	128
29	Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA. <i>Journal of Clinical Oncology</i> , 2004, 22, 3053-3060.	0.8	125
30	Population-based differences in treatment outcome following anticancer drug therapies. <i>Lancet Oncology</i> , The, 2010, 11, 75-84.	5.1	121
31	Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5115-E5124.	3.3	114
32	Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2005, 103, 22-31.	2.0	112
33	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2012, 23, 1287-1292.	0.6	111
34	The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22. <i>European Journal of Cancer</i> , 2009, 45, 1146-1152.	1.3	108
35	Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. <i>Oncogene</i> , 2007, 26, 7490-7498.	2.6	106
36	Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 714-720.	0.4	105

#	ARTICLE	IF	CITATIONS
37	Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions. <i>Cancer Science</i> , 2008, 99, 1311-1318.	1.7	102
38	Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. <i>Annals of Oncology</i> , 2011, 22, 1280-1287.	0.6	102
39	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	1.1	96
40	Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2012, 104, 300-304.	0.3	93
41	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 59-64.	1.1	82
42	The impact of ¹⁸ F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. <i>British Journal of Radiology</i> , 2008, 81, 291-298.	1.0	82
43	Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. <i>Cancer</i> , 2002, 95, 2516-2523.	2.0	81
44	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 340-347.	1.4	75
45	Update on the Management and Therapeutic Monitoring of Advanced Nasopharyngeal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1267-1278.	0.9	69
46	STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells <i>in vitro</i> . <i>International Journal of Cancer</i> , 2009, 125, 1884-1893.	2.3	67
47	Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2009, 15, 1005-1012.	3.2	65
48	Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 768-776.	1.5	61
49	Radiotherapy for nasopharyngeal carcinoma—transition from two-dimensional to three-dimensional methods. <i>Radiotherapy and Oncology</i> , 2004, 73, 163-172.	0.3	60
50	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018, 64, 1239-1249.	1.5	60
51	Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. <i>Annals of Oncology</i> , 2020, 31, 769-779.	0.6	60
52	The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. <i>Investigational New Drugs</i> , 2010, 28, 413-420.	1.2	58
53	Dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) for differential diagnosis in head and neck cancers. <i>European Journal of Radiology</i> , 2012, 81, 784-788.	1.2	58
54	The Metalloprotease ADAMTS8 Displays Antitumor Properties through Antagonizing EGFR-MEK-ERK Signaling and Is Silenced in Carcinomas by CpG Methylation. <i>Molecular Cancer Research</i> , 2014, 12, 228-238.	1.5	58

#	ARTICLE	IF	CITATIONS
55	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , 2010, 28, 107-114.	1.2	56
56	Predictive factors for overall quality of life in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2013, 21, 1709-1716.	1.0	56
57	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	3.0	56
58	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF- κ B activation and immune escape. <i>Nature Communications</i> , 2021, 12, 4193.	5.8	56
59	Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma—correlation with excision repair cross-complementing-1 polymorphisms. <i>Annals of Oncology</i> , 2009, 20, 1854-1859.	0.6	55
60	Advanced proteomic technologies for cancer biomarker discovery. <i>Expert Review of Proteomics</i> , 2009, 6, 123-134.	1.3	55
61	Liver Resection after Irinotecan, 5-Fluorouracil, and Folinic Acid for Patients with Unresectable Colorectal Liver Metastases: A Multicenter Phase II Study by the Cancer Therapeutic Research Group. <i>Medical Oncology</i> , 2005, 22, 303-312.	1.2	53
62	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 3984-3992.	2.0	53
63	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. <i>Nature Communications</i> , 2019, 10, 3256.	5.8	52
64	Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2019, 30, 977-982.	0.6	52
65	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2007, 253, 74-88.	3.2	50
66	Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer—a retrospective review of Chinese patients and comparison with an historic Western series. <i>Radiotherapy and Oncology</i> , 2002, 62, 185-189.	0.3	49
67	Head and Neck Tumors: Amide Proton Transfer MRI. <i>Radiology</i> , 2018, 288, 782-790.	3.6	47
68	Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. <i>Oral Oncology</i> , 2019, 88, 124-130.	0.8	46
69	Unresectable Hepatocellular Carcinoma: Randomized Controlled Trial of Transarterial Ethanol Ablation versus Transcatheter Arterial Chemoembolization. <i>Radiology</i> , 2014, 270, 607-620.	3.6	44
70	Phase 1 study of capmatinib in MET α positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020, 111, 536-547.	1.7	44
71	Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 2720-2729.	2.0	43
72	Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. <i>Supportive Care in Cancer</i> , 2011, 19, 1625-1635.	1.0	42

#	ARTICLE	IF	CITATIONS
73	Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Review of Anticancer Therapy, 2006, 6, 383-394.	1.1	41
74	Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study. Clinical Cancer Research, 2018, 24, 1030-1037.	3.2	41
75	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Investigational New Drugs, 2010, 28, 326-333.	1.2	40
76	Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. World Journal of Gastroenterology, 2014, 20, 3847.	1.4	40
77	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. Oncologist, 2016, 21, 292-300.	1.9	40
78	Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. Investigational New Drugs, 2013, 31, 567-575.	1.2	38
79	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data. BMC Cancer, 2017, 17, 8.	1.1	38
80	Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. Clinical Cancer Research, 2021, 27, 6413-6423.	3.2	37
81	Cure of Pulmonary Rhizomucor Pusillus Infection in a Patient with Hairy-Cell Leukemia: Role of Liposomal Amphotericin B and GM-CSF. Leukemia and Lymphoma, 2001, 42, 1393-1399.	0.6	35
82	Plasma Osteopontin, Hypoxia, and Response to Radiotherapy in Nasopharyngeal Cancer. Clinical Cancer Research, 2008, 14, 7080-7087.	3.2	35
83	Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. European Radiology, 2019, 29, 5627-5634.	2.3	35
84	Diffusion-Weighted Imaging of Nasopharyngeal Carcinoma: Can Pretreatment DWI Predict Local Failure Based on Long-Term Outcome?. American Journal of Neuroradiology, 2016, 37, 1706-1712.	1.2	34
85	Nasopharyngeal Cancers: Which Method Should be Used to Measure these Irregularly Shaped Tumors on Cross-Sectional Imaging?. International Journal of Radiation Oncology Biology Physics, 2007, 69, 148-154.	0.4	31
86	Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). Investigational New Drugs, 2015, 33, 985-991.	1.2	31
87	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. Journal of Clinical Oncology, 2014, 32, 2520-2520.	0.8	31
88	Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Letters, 2014, 343, 24-32.	3.2	30
89	Colorectal cancer in Chinese patients: current and emerging treatment options. OncoTargets and Therapy, 2014, 7, 1817.	1.0	29
90	441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Annals of Oncology, 2016, 27, .	0.6	29

#	ARTICLE	IF	CITATIONS
91	Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , 2011, 29, 1123-1131.	1.2	28
92	Management of Hepatocellular Carcinoma: Beyond Sorafenib. <i>Current Oncology Reports</i> , 2012, 14, 257-266.	1.8	27
93	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015, 33, 942-953.	1.2	27
94	Convolutional neural network for discriminating nasopharyngeal carcinoma and benign hyperplasia on MRI. <i>European Radiology</i> , 2021, 31, 3856-3863.	2.3	27
95	Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma—a prognostic evaluation and correlation with hypoxia inducible factor 1 α and vascular endothelial growth factor. <i>Oral Oncology</i> , 2007, 43, 373-378.	0.8	25
96	Radiation Injury of the Parotid Glands During Treatment for Head and Neck Cancer: Assessment Using Dynamic Contrast-Enhanced MR Imaging. <i>Radiation Research</i> , 2011, 175, 291-296.	0.7	25
97	Clinical Significance of Frizzled Homolog 3 Protein in Colorectal Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e79481.	1.1	25
98	Personalizing Therapy for Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 139-144.	2.4	25
99	Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma. <i>Scientific Reports</i> , 2018, 8, 8010.	1.6	25
100	Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , 2013, 31, 1399-1408.	1.2	24
101	Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1051-1055.	2.9	24
102	MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S407.	0.5	24
103	Investigational drugs for nasopharyngeal carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 677-685.	1.9	23
104	Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. <i>British Journal of Cancer</i> , 2011, 104, 1000-1006.	2.9	22
105	Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2021, 113, 105127.	0.8	21
106	Prospective validation of serum CYFRA 21-1, β -2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy. <i>Cancer</i> , 2004, 101, 776-781.	2.0	20
107	Pharmacoproteomics Study of Cetuximab in Nasopharyngeal Carcinoma. <i>Journal of Proteome Research</i> , 2006, 5, 3260-3267.	1.8	20
108	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , 2018, 14, 2031-2044.	1.1	20

#	ARTICLE	IF	CITATIONS
109	Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal Carcinoma. <i>American Journal of Neuroradiology</i> , 2020, 41, 515-521.	1.2	20
110	The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2008, 44, 1067-1072.	0.8	19
111	Novel systemic therapeutic for nasopharyngeal carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S63-S68.	1.5	19
112	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. <i>Clinical Colorectal Cancer</i> , 2017, 16, e73-e88.	1.0	19
113	Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. <i>Oncology Reports</i> , 0, , .	1.2	18
114	Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease. <i>Oral Oncology</i> , 2017, 69, 74-79.	0.8	18
115	Pre-treatment intravoxel incoherent motion diffusion-weighted imaging predicts treatment outcome in nasopharyngeal carcinoma. <i>European Journal of Radiology</i> , 2020, 129, 109127.	1.2	18
116	Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: A case report and review of the literature. <i>Annals of Oncology</i> , 2001, 12, 1015-1017.	0.6	17
117	Radiation-induced spinal glioblastoma multiforme. <i>Acta Oncologica</i> , 2006, 45, 87-90.	0.8	17
118	Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer—a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. <i>Annals of Oncology</i> , 2017, 28, 1576-1581.	0.6	17
119	Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma. <i>European Radiology</i> , 2020, 30, 6339-6347.	2.3	17
120	Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. <i>Cancer Science</i> , 2016, 107, 1477-1483.	1.7	16
121	Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. <i>Pathogens</i> , 2018, 7, 63.	1.2	16
122	Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 295-300.	1.1	15
123	Isolated Tumor Cells and Circulating CK20 mRNA in pN0 Colorectal Cancer Patients. <i>International Journal of Surgical Pathology</i> , 2008, 16, 119-126.	0.4	15
124	Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus. <i>Clinical Colorectal Cancer</i> , 2014, 13, 145-155.	1.0	15
125	Staging nodal metastases in nasopharyngeal carcinoma: which method should be used to measure nodal dimension on MRI?. <i>Clinical Radiology</i> , 2018, 73, 640-646.	0.5	15
126	Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC). <i>Cancer Research</i> , 2019, 79, CT150-CT150.	0.4	15

#	ARTICLE	IF	CITATIONS
127	Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2â€“ advanced breast cancer. <i>Cancer Research</i> , 2016, 76, P6-13-01-P6-13-01.	0.4	15
128	Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. <i>Biomedicine and Pharmacotherapy</i> , 2005, 59, S268-S271.	2.5	14
129	The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma. <i>Current Opinion in Oncology</i> , 2020, 32, 187-195.	1.1	14
130	Amide proton transfer MRI detects early changes in nasopharyngeal carcinoma: providing a potential imaging marker for treatment response. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 505-512.	0.8	13
131	Dynamic Changes of Post-Radiotherapy Plasma Epsteinâ€“Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2827-2836.	3.2	13
132	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6002-6002.	0.8	13
133	Clinical trial designs for targeted agents. <i>Hematology/Oncology Clinics of North America</i> , 2002, 16, 1287-1305.	0.9	12
134	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1417-1425.	1.1	12
135	Elucidating the prognostic significance of <sc><i>KRAS</i></sc>, <sc><i>NRAS</i></sc>, <sc><i>BRAF</i></sc> and <sc><i>PIK3CA</i></sc> mutations in <sc>C</sc>hinese patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 160-169.	0.7	12
136	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1255-1261.	1.5	12
137	Diffusion-weighted imaging of nasopharyngeal carcinoma to predict distant metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1045-1051.	0.8	12
138	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019, 49, 446-454.	0.5	12
139	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2008, 26, 6055-6055.	0.8	12
140	Intermittent versus continuous erlotinib with concomitant modified â€œXELOXâ€•(q3W) in firstâ€“line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2013, 119, 4145-4153.	2.0	11
141	The Effect of Centrifugal Force in Quantification of Colorectal Cancer-Related mRNA in Plasma Using Targeted Sequencing. <i>Frontiers in Genetics</i> , 2018, 9, 165.	1.1	11
142	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2â€“ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428.	3.2	11
143	Adjuvant Chemoradiation for Gastric Cancer: Experience in the Chinese Population. <i>Clinical Oncology</i> , 2007, 19, 333-340.	0.6	10
144	The effect of centrifugation on circulating mRNA quantitation opens up a new scenario in expression profiling from patients with metastatic colorectal cancer. <i>Clinical Biochemistry</i> , 2007, 40, 1277-1284.	0.8	10

#	ARTICLE	IF	CITATIONS
145	An update on the safety and efficacy of regorafenib in the treatment of solid cancers. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1607-1614.	1.5	10
146	Jagged 2 silencing inhibits motility and invasiveness of colorectal cancer cell lines. Oncology Letters, 2016, 12, 5193-5198.	0.8	10
147	Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles. Clinical Chemistry, 2020, 66, 598-605.	1.5	10
148	Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. Investigational New Drugs, 2013, 31, 30-38.	1.2	9
149	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. Oncologist, 2018, 23, 1436-1445.	1.9	9
150	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <sc>CONCUR</sc> trial. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1307-1316.	1.4	8
151	Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. BMC Cancer, 2006, 6, 259.	1.1	7
152	Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases. European Archives of Oto-Rhino-Laryngology, 2018, 275, 497-505.	0.8	7
153	Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer. Journal of Oncology, 2009, 2009, 1-6.	0.6	6
154	Previous Bevacizumab and Efficacy of Later Anti-“Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. Clinical Colorectal Cancer, 2018, 17, e593-e599.	1.0	6
155	Virtual microdissection in the molecular subtyping of head and neck squamous carcinoma“a” a “Virtual Reality”™ of the tumor microenvironment?. Annals of Oncology, 2019, 30, 8-10.	0.6	6
156	Quantitative T1•MRI of the Head and Neck Discriminates Carcinoma and Benign Hyperplasia in the Nasopharynx. American Journal of Neuroradiology, 2020, 41, 2339-2344.	1.2	6
157	A Novel Application of Plasma and Cerebrospinal Fluid Level of Epstein Barr Virus DNA in the Diagnosis of Leptomeningeal Metastasis from Nasopharyngeal Carcinoma. Oncology, 2008, 74, 119-122.	0.9	5
158	Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 225-230.	0.7	5
159	Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 270-280.	1.8	5
160	Global Implementation of Precision Oncology. JCO Precision Oncology, 2021, 5, 854-858.	1.5	5
161	The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. Nature Medicine, 2021, 27, 1512-1513.	15.2	5
162	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. Clinical Colorectal Cancer, 2021, 20, e21-e34.	1.0	4

#	ARTICLE	IF	CITATIONS
163	Efficacy of neoadjuvant docetaxel and cisplatin followed by concurrent cisplatin-radiotherapy in locally advanced nasopharyngeal carcinoma (NPC): A randomized phase II study. <i>Journal of Clinical Oncology</i> , 2007, 25, 6037-6037.	0.8	4
164	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5511-5511.	0.8	4
165	Case of chlorambucil-induced seizure. <i>Internal Medicine Journal</i> , 2006, 36, 683-684.	0.5	3
166	An unusual cause of superior vena cava obstruction. <i>Thorax</i> , 2006, 61, 182-182.	2.7	3
167	Advanced technologies for studying circulating tumor cells at the protein level. <i>Expert Review of Proteomics</i> , 2013, 10, 579-589.	1.3	3
168	500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2 ⁺ advanced/metastatic breast cancer: results from a Phase Ib clinical trial. <i>European Journal of Cancer</i> , 2014, 50, 163.	1.3	3
169	Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia ² Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 388-395.	0.7	3
170	Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT).. <i>Journal of Clinical Oncology</i> , 2010, 28, 5582-5582.	0.8	3
171	Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-na ⁺ ve or -refractory HR+, HER2-advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane. , 2018, , .		3
172	Update on Anti-EGFR Targeted Therapy. <i>Journal of Oncology</i> , 2009, 2009, 1-2.	0.6	2
173	Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. <i>Personalized Medicine</i> , 2010, 7, 121-124.	0.8	2
174	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. <i>Targeted Oncology</i> , 2021, 16, 227-236.	1.7	2
175	Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy. <i>Annals of Oncology</i> , 2019, 30, ix97-ix98.	0.6	2
176	Abstract 4602: Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines. <i>Cancer Research</i> , 2012, 72, 4602-4602.	0.4	2
177	Abstract CT076: Multicenter phase II study of nivolumab in previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma - Mayo clinic Phase 2 Consortium P2C-MN026, NCI9742, NCT02339558. , 2017, , .		2
178	A randomized phase II study of concurrent cisplatin-radiotherapy (RT) with or without neoadjuvant chemotherapy using docetaxel and cisplatin in advanced nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , 2005, 23, 5544-5544.	0.8	2
179	Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , 2008, 26, 3052-3052.	0.8	2
180	A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.. <i>Journal of Clinical Oncology</i> , 2011, 29, 2592-2592.	0.8	2

#	ARTICLE	IF	CITATIONS
181	A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).. Journal of Clinical Oncology, 2015, 33, 6031-6031.	0.8	2
182	Trends in phase 1 oncology drug development in East-Asia and Australia. Chinese Clinical Oncology, 2019, 8, 22-22.	0.4	2
183	Total Neoadjuvant Therapy for High Risk Rectal Cancer in Western and Asian Populations â€“ Current Evidence and Clinical Applications. Clinical Colorectal Cancer, 2022, 21, 45-54.	1.0	2
184	Transcriptional profiling of tumor biopsies in oncology trialsâ€”a â€“windowâ€™ of opportunity for evaluating new drugs in nasopharyngeal cancer?. Annals of Oncology, 2006, 17, 1611-1613.	0.6	1
185	Phase I investigatorâ€™s perceptions to â€“supersized seamless trials in oncology’. Annals of Oncology, 2018, 29, ix26.	0.6	1
186	A pilot case-control study of second or third-line treatment with cetuximab-containing chemotherapy (cetux-chemo) in patients (pts) with metastatic colorectal cancer (mCRC) who were previously treated with cetux-chemo. Annals of Oncology, 2018, 29, ix35.	0.6	1
187	Abstract 2100: Preclinical evaluation of PF-04691502 in nasopharyngeal carcinoma.. , 2013, , .		1
188	Abstract 3773: Preclinical evaluation of the CDK4/6 inhibitor LEE011 in nasopharyngeal carcinoma (NPC) cell lines. , 2016, , .		1
189	Prognostic system for hepatitis B virus (HBV)-related hepatocellular carcinoma- Prospective validation of the Chinese University Prognostic Index. Journal of Clinical Oncology, 2008, 26, 4591-4591.	0.8	1
190	The effect of cisplatin dose administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2011, 29, 5532-5532.	0.8	1
191	The expression of frizzled-3 receptor in colorectal cancer and colorectal adenoma.. Journal of Clinical Oncology, 2011, 29, 444-444.	0.8	1
192	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. Journal of Clinical Oncology, 2014, 32, 6029-6029.	0.8	1
193	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. Journal of Clinical Oncology, 2015, 33, 697-697.	0.8	1
194	The association between serum folate level and toxicity of capecitabine.. Journal of Clinical Oncology, 2016, 34, 3566-3566.	0.8	1
195	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. Journal of Clinical Oncology, 2018, 36, 3534-3534.	0.8	1
196	Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. Journal of Clinical Oncology, 2018, 36, 747-747.	0.8	1
197	Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa).. Journal of Clinical Oncology, 2013, 31, 425-425.	0.8	1
198	Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital. Hong Kong Medical Journal, 2016, 22, 546-55.	0.1	1

#	ARTICLE	IF	CITATIONS
199	A multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent capecitabine and radiotherapy for high risk rectal cancer: A final report. <i>Annals of Oncology</i> , 2019, 30, ix30.	0.6	1
200	Patterns of Local Failure Following Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: Predominance of Within-Field Failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S413-S414.	0.4	0
201	Phase 1 Study of MLN8237 (Alisertib) in Adult East Asian Patients (PTS) with Advanced Solid Tumors or Lymphomas. <i>Annals of Oncology</i> , 2013, 24, ix48.	0.6	0
202	2112 Association between early tumour shrinkage and outcomes in RAS-wild type patients with metastatic colorectal cancer receiving first-line FOLFOX or FOLFIRI + cetuximab once every 2 weeks in the APEC study. <i>European Journal of Cancer</i> , 2015, 51, S367.	1.3	0
203	2870 Prospective evaluation of both plasma Epstein Barr Virus (EBV) DNA clearance and fludeoxyglucose-positron emission tomography (PET-CT) as a dual-endpoint in predicting early response and survival of patients undergoing chemotherapy (chemo) for advanced nasopharyngeal carcinoma (NPC) (NCT01365208). <i>European Journal of Cancer</i> , 2015, 51, S580.	1.3	0
204	Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation. <i>Annals of Oncology</i> , 2016, 27, vi332.	0.6	0
205	Triplet Combination of Endocrine Therapy with CDK 4/6 Inhibitor, Ribociclib, and MTOR Inhibitor, Everolimus in HR+, HER2-ABC: Results from the Dose-Expansion Cohort. <i>Breast</i> , 2017, 36, S46-S47.	0.9	0
206	Mesenchymal stem cells: why intra-articular? A systematic review of animal studies and clinical evidence on MSC for knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2019, 27, S511-S512.	0.6	0
207	91P Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients. <i>Annals of Oncology</i> , 2020, 31, S1277-S1278.	0.6	0
208	Immediate toxicity among Chinese patients undergoing adjuvant doxorubicin and cyclophosphamide for early breast cancer- a single institute experience with comparison to historic Western series. <i>European Journal of Cancer</i> , 2002, 38, S132.	1.3	0
209	Serial alpha-feto protein in predicting radiological response and overall survival of patient with inoperable hepatocellular carcinoma (HCC) during chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 4602-4602.	0.8	0
210	Dose-volume analysis of radiation dermatitis among nasopharyngeal carcinoma patients treated with comcurrent cetuximab-cisplatin and intensity-modulated radiotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 17015-17015.	0.8	0
211	Does severity of underlying chronic liver disease (CLD) affect treatment outcome of hepatocellular carcinoma (HCC) patients undergoing systemic chemotherapy (CT)? <i>Journal of Clinical Oncology</i> , 2009, 27, e15513-e15513.	0.8	0
212	Abstract 853: Prognostic significance of VEGF mRNA in pN0 patients with colorectal cancer. , 2010, , .		0
213	Abstract 2190:ADAMTS8at 11q25 is a tumor suppressor antagonizing Ras-signaling and methylated in multiple carcinomas. , 2011, , .		0
214	Quantitation of circulating methylated RASSF1A in prognostication and monitoring of treatment response in unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4058-4058.	0.8	0
215	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e14501-e14501.	0.8	0
216	Abstract B273: Multicenter Phase II study of MK-2206 in previously treated patients (pts) with recurrent and metastatic nasopharyngeal carcinoma (NPC): Mayo Clinic Phase II Consortium (Protocol: MC1079).. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
217	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. Journal of Clinical Oncology, 2014, 32, 181-181.	0.8	0
218	Identifying an early indicator of drug efficacy in patients (pts) with metastatic colorectal cancer (mCRC): A prospective evaluation of circulating tumor cells (CTC), 18F-fluorodeoxyglucose positron-emission tomography (PET), and the RECIST criteria.. Journal of Clinical Oncology, 2014, 32, 3582-3582.	0.8	0
219	Abstract 5499: Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC) using 3D cell culture system. , 2014, , .		0
220	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 566-566.	0.8	0
221	Regional variation in physiciansâ€™ awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education.. Journal of Clinical Oncology, 2015, 33, 574-574.	0.8	0
222	Abstract 1734: Preclinical study of HSP-90 inhibitor drug, AUY922 showed good efficacy in treatment of nasopharyngeal cancer. , 2015, , .		0
223	Abstract 3776: Examination of ERCC1 status in circulating tumor cells as a prognostic tool for patients with nasopharyngeal carcinoma. , 2017, , .		0
224	Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases. Annals of Oncology, 2019, 30, ix124-ix125.	0.6	0
225	Vitamin E in prevention against hepatocellular carcinoma: right type, right dose and right population. Chinese Clinical Oncology, 2012, 1, 8.	0.4	0